Mucinous cystadenocarcinoma historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
'''For patient information, click [[Ovarian cancer (patient information)|here]]'''
{{Mucinous cystadenocarcinoma}}
{{Mucinous cystadenocarcinoma}}
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Qurrat}}, {{Ammu}}
 
==Overview==
==Overview==
In 1886, few [[pathologists]] in Chicago conducting [[experiments]] on mice to fond out the role of [[PTEN (gene)|PTEN]] [[mutation]] in [[cancer]] development found an association between [[PTEN]] [[mutation]] with the development of [[Mucinous cystadenocarcinoma|mucinous cystadenocarcinom]]<nowiki/>a. [[Mucinous cystadenocarcinoma]] of the [[renal pelvis]] was first described as a separate entity in 1960 by Hasebe et al.
In 1886, few [[pathologists]] in Chicago conducting [[experiments]] on mice to fond out the role of [[PTEN (gene)|PTEN]] [[mutation]] in [[cancer]] development found an association between [[PTEN]] [[mutation]] with the development of [[Mucinous cystadenocarcinoma|mucinous cystadenocarcinom]]<nowiki/>a. [[Mucinous cystadenocarcinoma]] of the [[renal pelvis]] was first described as a separate entity in 1960 by Hasebe et al.

Revision as of 14:34, 22 April 2019

For patient information, click here

Mucinous cystadenocarcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Mucinous Cystadenocarcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mucinous cystadenocarcinoma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mucinous cystadenocarcinoma historical perspective

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mucinous cystadenocarcinoma historical perspective

CDC on Mucinous cystadenocarcinoma historical perspective

Mucinous cystadenocarcinoma historical perspective in the news

Blogs on Mucinous cystadenocarcinoma historical perspective

Directions to Hospitals Treating Mucinous cystadenocarcinoma

Risk calculators and risk factors for Mucinous cystadenocarcinoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Ammu Susheela, M.D. [3]

Overview

In 1886, few pathologists in Chicago conducting experiments on mice to fond out the role of PTEN mutation in cancer development found an association between PTEN mutation with the development of mucinous cystadenocarcinoma. Mucinous cystadenocarcinoma of the renal pelvis was first described as a separate entity in 1960 by Hasebe et al.

Discovery

References

  1. "www.nature.com" (PDF).
  2. HASEBE M, SERIZAWA S, CHINO S (1960). "[On a case of papillary cystadenocarcinoma following malignant degeneration of a papillary adenoma in the kidney pelvis]". Yokohama Med Bull. 11: 491–500. PMID 13712095.

Template:WH Template:WS